In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL

Visa fullständig post



Permalänk

http://hdl.handle.net/10138/224428

Citation

Laukkanen , S , Gronroos , T , Polonen , P , Kuusanmaki , H , Mehtonen , J , Cloos , J , Ossenkoppele , G , Gjertsen , B , Oystein , B , Heckman , C , Heinaniemi , M , Kontro , M & Lohi , O 2017 , ' In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL ' , Blood cancer journal , vol. 7 , 604 . https://doi.org/10.1038/bcj.2017.87

Titel: In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL
Författare: Laukkanen, S.; Gronroos, T.; Polonen, P.; Kuusanmaki, H.; Mehtonen, J.; Cloos, J.; Ossenkoppele, G.; Gjertsen, B.; Oystein, B.; Heckman, C.; Heinaniemi, M.; Kontro, M.; Lohi, O.
Upphovmannens organisation: Institute for Molecular Medicine Finland
University of Helsinki
Clinicum
Hematologian yksikkö
Department of Oncology
HUS Comprehensive Cancer Center
Datum: 2017-09-08
Språk: eng
Sidantal: 4
Tillhör serie: Blood cancer journal
ISSN: 2044-5385
DOI: https://doi.org/10.1038/bcj.2017.87
Permanenta länken (URI): http://hdl.handle.net/10138/224428
Subject: ACUTE LYMPHOBLASTIC-LEUKEMIA
CELL-ACTIVATION
KINASE INHIBITOR
SENSITIVITY
EXPERIENCE
REMISSION
PATIENT
LCK
3122 Cancers
Referentgranskad: Ja
Licens: cc_by
Användningsbegränsning: openAccess
Parallelpublicerad version: publishedVersion


Filer under denna titel

Totalt antal nerladdningar: Laddar...

Filer Storlek Format Granska
bcj201787a.pdf 669.6Kb PDF Granska/Öppna

Detta dokument registreras i samling:

Visa fullständig post